Announced
Completed
Financials
Sources
Tags
asthma diagnostic products
Medical Equipment
Sweden
Public
Completed
Friendly
Single Bidder
Synopsis
Circassia Pharmaceuticals, a specialty biopharmaceutical company, agreed to acquire Aerocrine, a Swedish listed company focused on the development and commercialisation of medical diagnostic products for use in the diagnosis and management of patients with asthma, for a total consideration of up to SEK 1.78bn (approximately £139m). “These proposed acquisitions and associated fundraising significantly accelerate Circassia’s strategy to become a self-sustaining specialty biopharmaceutical company focused on allergy and asthma. The combined organisation will give us both the capability and resources to commercialise our enlarged late-stage pipeline of potential new allergy and asthma products, once approved, and thereby generate significant shareholder value," Steve Harris, Circassia CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.